ABPI Respond To UK PM's Brexit Speech
The UK pharmaceutical industry trade body, the Association of the British Pharmaceutical Industry (ABPI), have responded to the Prime Minister's speech on the Government's negotiating objectives for exiting the EU.
Theresa May's speech was delivered today (Tuesday 17 January) at Lancaster House, and set out the 12 negotiating priorities for Brexit as part of the Plan for Britain after leaving the EU.
“Today’s announcement is a welcome statement of intent that provides the UK’s pharmaceutical industry with confidence for the future."
The ABPI is pleased that the Prime Minister has identified Britain becoming the best place for science and innovation as one of her twelve negotiation priorities. Our continued leadership in this area will be crucial in creating a truly ‘global Britain’.
The Prime Minister has also said today that the UK’s new relationship with the EU will be set out by the end of the two-year period following the triggering of Article 50. Throughout this period, we will seek to secure the UK’s continued cooperation and alignment with EU rules for the regulation of medicines. This will be the best possible outcome for UK patients.
We look forward to continuing to work with Government to make a success of the UK leaving the EU, securing a deal that builds upon our status as a global pharmaceutical industry leader."
Mike Thompson, ABPI, Chief Executive
Prof. Ruth Roberts Receives International Award for Drug and Chemical Safety WorkNews
Professor Ruth Roberts – co-founder and director of nonclinical safety company, ApconiX based at Alderley Park, Cheshire – is the first non-US-based scientist to receive a prestigious international award for professionals specialising in drug and chemical safety.READ MORE
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
Salmonella Cases No Longer Declining in the EUNews
The declining trend of salmonellosis cases in the EU has levelled off according to the annual report on zoonotic diseases. Cases of Salmonella Enteritidis acquired in the EU have increased in humans by 3% since 2014 and in laying hens, the prevalence increased from 0.7% to 1.21% over the same period.